SALT LAKE CITY, June 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a collaboration with GSK aimed at improving access to homologous recombination deficiency (HRD) diagnostic testing for high-grade serous ovarian cancer (HGSOC) patients. A new sponsored testing program leveraging Myriad’s MyChoice HRD Plus and MyChoice CDx Plus Tests (collectively referred to as Myriad’s MyChoice Tests) is now available in Argentina, Brazil, Chile, Colombia, Egypt, Netherlands, Saudia Arabia, Singapore, and United Arab Emirates.
HRD testing is an important predictive and prognostic biomarker for patients who have ovarian cancer. Myriad’s MyChoice Tests determine HRD status in women with ovarian cancer. Clinicians can order this test through their local pathology labs and samples are sent to Myriad Genetics.
This collaboration delivers on both companies’ shared commitment to improve care for patients with advanced ovarian cancer by facilitating access to genetic testing and demonstrates a mutual dedication to meeting an unmet need for patients who otherwise may not have access to testing.
“Our collaboration with GSK is an important step forward in providing critical genetic insights that can help clinicians guide more personalized ovarian cancer treatment decisions,” said Patrick Burke, PhD, EVP of Strategy and Innovation, Myriad Genetics. “In the pursuit of advancing healthcare equity, Myriad is committed to extending the reach of our diagnostic solutions, like Myriad’s MyChoice Tests into additional markets to support more targeted patient care based on their genomic profile.”
About Myriad’s MyChoice Test
Myriad’s MyChoice® test is the most comprehensive tumor test for determining HRD status based on the assessment of genomic alterations in genes such as BRCA1 and BRCA2 and Genomic Instability Score (GIS) status using Myriad’s proprietary algorithm. It enables healthcare professionals to identify patients with advanced ovarian cancer who are more likely to respond to treatment with targeted therapies.
About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.
Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including that this collaboration will increase access to HRD testing and can help clinicians guide more personalized ovarian cancer treatment decisions for patients. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 28, 2024, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.
Investor Contact
Matt Scalo
(801) 584-3532
IR@myriad.com
Media Contact
Glenn Farrell
(385) 318-3718
PR@myriad.com
source: Myriad Genetics, Inc.
《說說心理話》 消費能獲取快樂？買不起，不如花光錢錢$$？「習得性無助」有何影響？一起看看正確理財觀念。► 即睇
